
|Articles|November 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 11
- Volume 5
- Issue 11
FDA Approves Xillix LIFE-Lung System
ROCKVILLE, Md-The FDA has given final approval to the Xillix LIFE-Lung Fluorescence Endoscopy System for use in detecting early lung cancer. Xillix Technologies Corp., of Richmond, British Columbia, plans to market the system worldwide in early 1997.
Advertisement
ROCKVILLE, MdThe FDA has given final approval to the Xillix LIFE-Lung Fluorescence Endoscopy System for use in detecting early lung cancer. Xillix Technologies Corp., of Richmond, British Columbia, plans to market the system worldwide in early 1997.
Articles in this issue
almost 30 years ago
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clustersalmost 30 years ago
AIDS Funding Increased for Fiscal '97almost 30 years ago
'Cancer Rates and Risks' Availablealmost 30 years ago
New Breast Cancer Patient Resource Is Availablealmost 30 years ago
Short-Term Metronidazole not Linked to Canceralmost 30 years ago
Various Capitation Models Are Available for Oncology Networksalmost 30 years ago
NCI Urges full Disclosure of Cigarette Contentsalmost 30 years ago
Antifungal Resistance on the Increasealmost 30 years ago
Fentanyl Patch Useful Alternative in Cancer Pain Patientsalmost 30 years ago
Analysis of Microvessel Density Predicts Extraprostatic SpreadAdvertisement
Related to this article

The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.

Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Advertisement
Advertisement
Trending on CancerNetwork
1
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
2
RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs
3
Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence
4
Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma
5

